Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features

Albarel F, Gaudy C, Castinetti F et al (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172(2):195–204. https://doi.org/10.1530/EJE-14-0845

Article  CAS  PubMed  Google Scholar 

Albarel F, Castinetti F, Brue T (2019) Management of endocrine disease: Immune check point inhibitors-induced hypophysitis. Eur J Endocrinol 181(3):R107–R118. https://doi.org/10.1530/EJE-19-0169

Article  CAS  PubMed  Google Scholar 

Araujo PB, Coelho MCA, Arruda M, Gadelha MR, Neto LV (2015) Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest 38(11):1159–1166. https://doi.org/10.1007/s40618-015-0301-z

Article  CAS  PubMed  Google Scholar 

Attia P, Phan GQ, Maker A et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23(25):6043–6053. https://doi.org/10.1200/JCO.2005.06.205

Article  CAS  PubMed  Google Scholar 

Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L (2018) Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer 124(6):1111–1121. https://doi.org/10.1002/cncr.31200

Article  CAS  PubMed  Google Scholar 

Blansfield JA, Beck KE, Tran K et al (2005) Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28(6):593–598. https://doi.org/10.1097/01.cji.0000178913.41256.06

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768. https://doi.org/10.1200/JCO.2017.77.6385

Article  CAS  PubMed  Google Scholar 

Broersen LHA, Pereira AM, Jørgensen JOL, Dekkers OM (2015) Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 100(6):2171–2180. https://doi.org/10.1210/jc.2015-1218

Article  CAS  PubMed  Google Scholar 

Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195–207. https://doi.org/10.1038/nrendo.2016.205

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castinetti F, Albarel F, Archambeaud F et al (2019) French endocrine society guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 26(2):G1–G18. https://doi.org/10.1530/ERC-18-0320

Article  CAS  PubMed  Google Scholar 

Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40(1):17–65. https://doi.org/10.1210/er.2018-00006

Article  PubMed  Google Scholar 

Cooksley T, Knight T, Lindsay D et al (2023) Immune checkpoint inhibitor-mediated hypophysitis: no place like home. Clin Med 23(1):81–84. https://doi.org/10.7861/clinmed.2022-0429

Article  Google Scholar 

Darzy KH (2009) Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab 5(2):88–99. https://doi.org/10.1038/ncpendmet1051

Article  CAS  PubMed  Google Scholar 

de Filette J, Andreescu C, Cools F, Bravenboer B, Velkeniers B (2019) A Systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 51(03):145–156. https://doi.org/10.1055/a-0843-3366

Article  CAS  PubMed  Google Scholar 

de Sousa SMC, Sheriff N, Tran CH et al (2018) Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary 21(3):274–282. https://doi.org/10.1007/s11102-018-0866-6

Article  CAS  PubMed  Google Scholar 

Esfahani K, Roudaia L, Buhlaiga N, del Rincon SV, Papneja N, Miller WH (2020) A Review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27(12):87–97. https://doi.org/10.3747/co.27.5223

Article  Google Scholar 

Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19(1):82–92. https://doi.org/10.1007/s11102-015-0671-4

Article  CAS  PubMed  Google Scholar 

Faje AT, Sullivan R, Lawrence D et al (2014) Ipilimumab-Induced Hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99(11):4078–4085. https://doi.org/10.1210/jc.2014-2306

Article  CAS  PubMed  Google Scholar 

Faje AT, Lawrence D, Flaherty K et al (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124(18):3706–3714. https://doi.org/10.1002/cncr.31629

Article  CAS  PubMed  Google Scholar 

Faje A, Reynolds K, Zubiri L et al (2019) Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol 181(3):211–219. https://doi.org/10.1530/EJE-19-0238

Article  CAS  PubMed  Google Scholar 

Fucà G, Galli G, Poggi M et al (2019) Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 4(1):000457. https://doi.org/10.1136/ESMOOPEN-2018-000457

Article  Google Scholar 

Hamnvik OPR, Larsen PR, Marqusee E (2011) Thyroid dysfunction from antineoplastic agents. JNCI J National Cancer Inst 103(21):1572–1587. https://doi.org/10.1093/jnci/djr373

Article  CAS  Google Scholar 

Higham CE, Olsson-Brown A, Carroll P et al (2018) Society For Endocrinology Endocrine Emergency Guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7(7):G1–G7. https://doi.org/10.1530/EC-18-0068

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hypophysitis FA (2016) Evaluation and Management. Clin Diabetes Endocrinol 2(1):15. https://doi.org/10.1186/s40842-016-0034-8

Article  Google Scholar 

Iravani A, Osman MM, Weppler AM et al (2020) FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Eur J Nucl Med Mol Imaging 47(12):2776–2786. https://doi.org/10.1007/s00259-020-04815-w

Article  CAS  PubMed  Google Scholar 

Iwama S, de Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 Mediates hypophysitis secondary to administration of CTLA-4 Blocking antibody. Sci Transl Med. 6(230):332. https://doi.org/10.1126/scitranslmed.3008002

Article  CAS  Google Scholar 

Joshi MN, Whitelaw BC, Palomar MTP, Wu Y, Carroll PV (2016) Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (oxf) 85(3):331–339. https://doi.org/10.1111/cen.13063

Article  CAS  PubMed  Google Scholar 

Kroemer G, Zitvogel L (2021) Immune checkpoint inhibitors. J Exper Med. https://doi.org/10.1084/jem.20201979

Article  Google Scholar 

Kuehn HS, Ouyang W, Lo B et al (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345(6204):1623–1627. https://doi.org/10.1126/science.1255904

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lasocki A, Iravani A, Galligan A (2021) The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients. Clin Radiol 76(5):325–332. https://doi.org/10.1016/j.crad.2020.12.028

Article  CAS  PubMed  Google Scholar 

Laurent S, Queirolo P, Boero S et al (2013) The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med 11(1):108. https://doi.org/10.1186/1479-5876-11-108

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maker AV, Yang JC, Sherry RM et al (2006) Intrapatient dose escalation of anti–ctla-4 antibody in patients with metastatic melanoma. J Immun 29(4):455–463. https://doi.org/10.1097/01.cji.0000208259.73167.58

Article  CAS  Google Scholar 

Min L, Vaidya A, Becker C (2012) Association of Ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 18(3):351–355. https://doi.org/10.4158/EP11273.OR

Article  PubMed  PubMed Central  Google Scholar 

Min L, Hodi FS, Giobbie-Hurder A et al (2015) Systemic High-dose corticosteroid treatment does not improve the outcome of Ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21(4):749–755. https://doi.org/10.1158/1078-0432.CCR-14-2353

Article  CAS  PubMed  Google Scholar 

Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38. https://doi.org/10.1038/s41572-020-0160-6

Article  PubMed  PubMed Central  Google Scholar 

Romano E, Kusio-Kobialka M, Foukas PG et al (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci 112(19):6140–6145. https://doi.org/10.1073/pnas.1417320112

Article  CAS  PubMed  PubMed Central 

留言 (0)

沒有登入
gif